Synlogic presents data demonstrating reductions in plasma phenylalanine levels in patients with phenylketonuria treated with synb1618

Cambridge, mass., nov. 22, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company's phase 2 synpheny-1 clinical trial showing that treatment with the investigational synthetic biotictm medicine synb1618 resulted in significant reductions in plasma phenylalanine (phe) levels in patients with phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking